| Bioactivity | MyoMed-205 is an inhibitor targeting the activity of MuRF1. MyoMed-205 prevents early diaphragmatic systolic dysfunction and atrophy due to unilateral diaphragmatic nerve denervation 12 hours later. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed-205 increases levels of a protein that phosphorylates Akt (ser473), an important signaling molecule for muscle growth and maintenance. MyoMed-205 can be used to study and treat diaphragmatic dysfunction and atrophy (DIDD) caused by early apraxia, especially in clinical situations such as diaphragmatic paralysis or mechanical ventilation[1]. |
| CAS | 2614161-13-4 |
| Formula | C26H25N3O5S |
| Molar Mass | 491.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ribeiro F, et al. Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy[J]. International Journal of Molecular Sciences, 2023, 24(4): 3637. |
MyoMed 205
CAS: 2614161-13-4 F: C26H25N3O5S W: 491.56
MyoMed-205 is an inhibitor targeting the activity of MuRF1. MyoMed-205 prevents early diaphragmatic systolic dysfunction
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.